Company Filing History:
Years Active: 2024
Title: The Innovative Contributions of Sang-Jun Ha
Introduction
Sang-Jun Ha is a notable inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of cancer therapeutics through his innovative research and development of antibodies.
Latest Patents
Sang-Jun Ha holds a patent for an "Anti-B7-H3 antibody and use thereof." This patent describes an antibody that specifically recognizes B7-H3, which is useful as a cancer therapeutic agent. The antibody exhibits inhibitory activity of an immune checkpoint, inducing antibody-dependent cell-mediated cytotoxicity and T cell activation that is inhibited by B7-H3. This innovative antibody can be used in combination with other immunoantibody therapeutic agents and is particularly valuable for cancer targeting treatment. It allows for the detection of various cancers expressing B7-H3 through specific binding and facilitates drug delivery to specific cancer types.
Career Highlights
Sang-Jun Ha is currently associated with Abl Bio Inc., where he continues to advance his research in immunotherapy. His work has positioned him as a key figure in the development of novel cancer treatments.
Collaborations
He collaborates with talented coworkers, including Kyeongsu Park and Yangsoon Lee, who contribute to the innovative environment at Abl Bio Inc.
Conclusion
Sang-Jun Ha's work in developing the Anti-B7-H3 antibody exemplifies the potential of innovative research in cancer therapy. His contributions are paving the way for new treatment options that could significantly impact patient care.